Ibogaine is a naturally occurring psychoactive compound extracted from the root bark of Tabernanthe iboga, a shrub native to Central West Africa. For more than half a century, observational reports and small clinical studies have documented its ability to interrupt opioid withdrawal and produce a single, prolonged psychedelic-like experience that many patients describe as therapeutically meaningful. In recent years, peer-reviewed research has begun to catch up to those reports — most notably a January 2024 study published in Nature Medicine on Special Operations veterans with traumatic brain injuries.
This article is a factual primer: what ibogaine is, how treatment is typically structured, what conditions it’s currently used for, and where it can be legally administered. We make no efficacy claims; this is educational material designed to help you ask the right questions before researching further.
How ibogaine works
Ibogaine acts on multiple receptor systems in the brain — including opioid, serotonin, sigma, and NMDA receptors — and produces a long-acting metabolite, noribogaine, that remains active for days after a single dose. The two effects most commonly cited in clinical literature are:
- Acute interruption of opioid withdrawal. Patients who have been physically dependent on heroin, fentanyl, methadone, suboxone, or prescription opioids report that withdrawal symptoms diminish or stop within hours of dosing.
- A 12-to-36-hour psychedelic-like state during which patients commonly report autobiographical reflection, vivid visual phenomena, and what some clinicians describe as “neuroplasticity windows” — periods after dosing during which behavioral patterns appear more flexible.
Researchers are still working to characterize the mechanism of action. Ibogaine is not a cure, and the experience is not pleasant in any conventional sense — patients describe it as physically demanding and emotionally intense. The clinical interest is in the aftermath, not the experience itself.
What ibogaine treatment looks like
Programs vary widely, but a medically supervised treatment course typically follows this arc:
Pre-treatment screening (1–4 weeks before)
Reputable clinics require:
- Cardiac evaluation. Ibogaine prolongs the QT interval and has been linked to fatal arrhythmias when administered without proper screening. Expect an EKG, electrolyte panel (especially magnesium and potassium), and a review of cardiac history. Some clinics now use magnesium pre-treatment specifically to mitigate cardiac risk — the protocol used in the Stanford 2024 study.
- Medical history review. Liver and kidney function, current medications, drug interactions.
- Taper protocol for opioid users. Long-acting opioids like methadone and suboxone require specific tapering before ibogaine; fentanyl introduces additional protocol considerations because of its potency and accumulation in adipose tissue.
Dosing day (24–48 hours)
Treatment occurs in a clinical setting with continuous medical monitoring. Patients receive a weight-based oral dose; some clinics use IV ibogaine. The acute experience lasts roughly 12 hours, followed by a “gray day” of reduced energy and altered mood. Reputable clinics maintain continuous EKG monitoring and have ACLS-certified medical staff and emergency drugs on site throughout.
Integration phase (days to months)
Most clinics include 2–7 days of post-treatment support on site — therapy, bodywork, integration sessions. The longer integration arc — therapy, behavioral changes, community support — is largely arranged by the patient afterward. We cover this in Aftercare and integration: what happens after ibogaine treatment.
What conditions are ibogaine providers treating?
Most operating clinics work primarily with opioid use disorder — fentanyl, heroin, methadone tapering, prescription opioids — because the acute withdrawal-interruption effect is the most replicated finding in the literature. Many clinics also accept patients seeking treatment for:
- Alcohol use disorder
- Cocaine, methamphetamine, and other stimulant dependence
- Benzodiazepine dependence (with specific tapering protocols)
- PTSD, including combat-related PTSD in veterans
- Treatment-resistant depression
- Anxiety
- Traumatic brain injury (the focus of the Stanford 2024 study)
The evidence base varies significantly by indication. Opioid withdrawal interruption is the strongest claim. Mental-health applications are still emerging. None of these uses are FDA-approved.
Where is ibogaine legal?
Ibogaine is Schedule I in the United States — meaning it has no accepted medical use under federal law and cannot be commercially administered. Patients seeking treatment have historically traveled to countries where ibogaine is not specifically scheduled, including:
- Mexico — the most common destination; not specifically scheduled under Mexican federal drug law
- Costa Rica — similar regulatory framework to Mexico
- Portugal — therapeutic use available under medical supervision in licensed clinics
- Bahamas — ibogaine clinics have operated under medical regulation for over a decade
- Netherlands — gray area; not specifically scheduled but not formally authorized
For a more detailed jurisdiction-by-jurisdiction breakdown, see Where is ibogaine legal? A jurisdiction-by-jurisdiction guide.
The legal landscape is shifting. Texas approved $50 million for state-funded ibogaine clinical trials in 2025, and the federal NDAA Section 723 (FY2024) authorizes the Department of Defense to fund psychedelic clinical trials — including ibogaine — for active-duty service members with PTSD and TBI. None of this changes the immediate legal status: clinical access for civilians still requires international travel.
Safety considerations
Ibogaine is not safe in the way that supplements are safe. The two principal risk categories are:
- Cardiac. QT-interval prolongation has caused arrhythmias and deaths. Pre-treatment cardiac screening, magnesium pre-loading, continuous EKG monitoring during dosing, and ACLS-trained staff are non-negotiable in well-run programs. Several documented deaths have occurred in settings without adequate screening or monitoring.
- Drug interactions. Many psychiatric medications — including SSRIs and MAOIs — must be tapered well before treatment. Methadone presents specific challenges due to its long half-life. Benzodiazepines, certain heart medications, and alcohol all introduce additional risk.
The quality bar across providers varies enormously. We’ve written a separate guide focused entirely on this question: How to choose an ibogaine clinic: a safety checklist.
What this site is for
We maintain a directory of medically supervised ibogaine providers across Mexico, Portugal, Bahamas, and other jurisdictions where treatment is legally available. Every listing carries a verification status — when we last verified the listing’s information, and through what source. We don’t accept payment from clinics for inclusion, ranking, or featured placement.
If you’re researching treatment, the next steps usually look like:
- Read Ibogaine treatment cost: what to expect to set financial expectations
- Read How to choose an ibogaine clinic: a safety checklist — this is the most important article we publish
- Read Aftercare and integration: what happens after ibogaine treatment to understand the work that begins after the clinic
- Browse verified providers by location and treatment focus
If you’re a veteran or active-duty service member, see Ibogaine for veterans: federal recognition and the access gap for an overview of the federal-investment / clinical-access asymmetry and the nonprofits currently funding access abroad.
This information is for educational purposes only and is not medical advice. Always consult a qualified healthcare provider before making decisions about treatment.